Tandem Diabetes Care Stock Cash And Equivalents

TNDM Stock  USD 30.81  0.07  0.23%   
Tandem Diabetes Care fundamentals help investors to digest information that contributes to Tandem Diabetes' financial success or failures. It also enables traders to predict the movement of Tandem Stock. The fundamental analysis module provides a way to measure Tandem Diabetes' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tandem Diabetes stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Tandem Diabetes Care Company Cash And Equivalents Analysis

Tandem Diabetes' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.

Cash

 = 

Bank Deposits

+

Liquidities

More About Cash And Equivalents | All Equity Analysis

Current Tandem Diabetes Cash And Equivalents

    
  608.73 M  
Most of Tandem Diabetes' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Tandem Diabetes Care is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Tandem Cash And Equivalents Driver Correlations

Understanding the fundamental principles of building solid financial models for Tandem Diabetes is extremely important. It helps to project a fair market value of Tandem Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since Tandem Diabetes' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Tandem Diabetes' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Tandem Diabetes' interrelated accounts and indicators.
0.880.9-0.860.820.990.970.961.0-0.020.780.970.780.560.850.980.930.90.580.60.970.960.97
0.880.63-0.760.650.880.90.720.9-0.140.910.770.450.610.890.830.810.90.560.630.920.920.74
0.90.63-0.790.810.890.870.970.880.210.540.930.890.450.690.890.840.760.560.530.840.840.95
-0.86-0.76-0.79-0.9-0.89-0.81-0.81-0.85-0.19-0.85-0.92-0.78-0.24-0.87-0.84-0.94-0.89-0.78-0.82-0.78-0.78-0.83
0.820.650.81-0.90.840.730.830.80.220.720.870.80.110.770.770.870.780.650.670.720.720.81
0.990.880.89-0.890.840.980.940.99-0.010.820.960.760.540.90.970.960.930.660.670.970.970.95
0.970.90.87-0.810.730.980.920.99-0.080.780.910.690.670.860.960.90.890.560.590.980.980.93
0.960.720.97-0.810.830.940.920.940.060.620.970.880.490.760.950.890.830.550.540.910.90.98
1.00.90.88-0.850.80.990.990.94-0.050.80.950.740.60.870.970.920.910.580.60.980.980.95
-0.02-0.140.21-0.190.22-0.01-0.080.06-0.05-0.080.090.12-0.19-0.07-0.17-0.03-0.060.230.38-0.08-0.090.0
0.780.910.54-0.850.720.820.780.620.8-0.080.740.470.350.920.760.840.90.590.760.790.790.66
0.970.770.93-0.920.870.960.910.970.950.090.740.880.420.810.950.930.870.630.630.890.880.98
0.780.450.89-0.780.80.760.690.880.740.120.470.880.130.560.810.790.640.470.420.640.630.89
0.560.610.45-0.240.110.540.670.490.6-0.190.350.420.130.390.550.350.460.140.170.690.680.49
0.850.890.69-0.870.770.90.860.760.87-0.070.920.810.560.390.830.920.970.730.830.890.890.76
0.980.830.89-0.840.770.970.960.950.97-0.170.760.950.810.550.830.930.890.540.530.940.940.97
0.930.810.84-0.940.870.960.90.890.92-0.030.840.930.790.350.920.930.920.70.750.880.880.91
0.90.90.76-0.890.780.930.890.830.91-0.060.90.870.640.460.970.890.920.730.780.920.920.82
0.580.560.56-0.780.650.660.560.550.580.230.590.630.470.140.730.540.70.730.80.580.580.54
0.60.630.53-0.820.670.670.590.540.60.380.760.630.420.170.830.530.750.780.80.610.620.51
0.970.920.84-0.780.720.970.980.910.98-0.080.790.890.640.690.890.940.880.920.580.611.00.9
0.960.920.84-0.780.720.970.980.90.98-0.090.790.880.630.680.890.940.880.920.580.621.00.89
0.970.740.95-0.830.810.950.930.980.950.00.660.980.890.490.760.970.910.820.540.510.90.89
Click cells to compare fundamentals
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Competition

Tandem Cash And Cash Equivalents Changes

Cash And Cash Equivalents Changes

121.36 Million

At this time, Tandem Diabetes' Cash And Cash Equivalents Changes is very stable compared to the past year.
In accordance with the recently published financial statements, Tandem Diabetes Care has 608.73 M in Cash And Equivalents. This is 25.84% lower than that of the Health Care Equipment & Supplies sector and 9.1% higher than that of the Health Care industry. The cash and equivalents for all United States stocks is 77.47% higher than that of the company.

Tandem Cash And Equivalents Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tandem Diabetes' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tandem Diabetes could also be used in its relative valuation, which is a method of valuing Tandem Diabetes by comparing valuation metrics of similar companies.
Tandem Diabetes is currently under evaluation in cash and equivalents category among its peers.

Tandem Diabetes ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Tandem Diabetes' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Tandem Diabetes' managers, analysts, and investors.
Environmental
Governance
Social

Tandem Fundamentals

About Tandem Diabetes Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Tandem Diabetes Care's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tandem Diabetes using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tandem Diabetes Care based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Tandem Diabetes Care is a strong investment it is important to analyze Tandem Diabetes' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Tandem Diabetes' future performance. For an informed investment choice regarding Tandem Stock, refer to the following important reports:
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.37)
Earnings Share
(1.94)
Revenue Per Share
13.082
Quarterly Revenue Growth
0.314
Return On Assets
(0.1)
The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.